(2Z,4E,6E,8E)-N-乙基-3,7-二甲基-9-(2,6,6-三甲基-1-环己烯基)壬-2,4,6,8-四烯酰胺 | 75686-04-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: (2Z,4E,6E,8E)-N-乙基-3,7-二甲基-9-(2,6,6-三甲基-1-环己烯基)壬-2,4,6,8-四烯酰胺
• 英文名称: 13-cis-N-Ethylretinamide
• 英文别名: Retinamide, N-ethyl-, 13-cis-；(2Z,4E,6E,8E)-N-ethyl-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
• CAS: 75686-04-3
• 化学式: C₂₂H₃₃NO
• 分子量: 327.51
• InChiKey: WKYDOCGICAMTKE-HAPIZUAHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  异维A酸 在 三氯化磷 作用下， 以 苯 为溶剂， 反应 3.5h， 生成 (2Z,4E,6E,8E)-N-乙基-3,7-二甲基-9-(2,6,6-三甲基-1-环己烯基)壬-2,4,6,8-四烯酰胺
  参考文献：
  名称：

  某些13-顺式和全反式视黄酰胺的合成和性质

  摘要：

  通过13-顺-视黄酰氯或13-顺-1-视黄基咪唑从13-顺-视黄酸合成了几种13-顺-视黄酰胺。由全反式视黄酰氯和甘氨酸乙酯制备全反式视黄酰甘氨酸。开发了用于制备其他全反式维甲酸酰胺的详细程序，以用于癌症化学预防的研究。

  DOI：

  10.1002/jps.2600730610

文献信息

• Insulin-producing cells derived from stem cells
  申请人：Hori Yuichi

  公开号：US20070154981A1

  公开（公告）日：2007-07-05

  The disclosure provides, among other things, insulin-producing cells derived from stem cells, such as human stem cells and neural stem cells. The disclosure discloses a relationship between caudalizing factors and the differentiation of insulin-producing cells.

  该披露提供了从干细胞（如人类干细胞和神经干细胞）衍生出的胰岛素产生细胞，其中包括其他内容。该披露揭示了尾端因子与胰岛素产生细胞分化之间的关系。
• Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes
  申请人：Board of Regents, The University of Texas System

  公开号：US20020143062A1

  公开（公告）日：2002-10-03

  Disclosed herein are simple and unique methods of methods of preparing liposomal compositions of N-(4-hydroxyphenyl) retinamide (4HPR) and/or other retinoids. Also disclosed are liposomal 4HPR compositions prepared by such methods, and use of such compositions in the treatment of diseases, such as breast cancer. This invention further provides methods for improving the efficacy of N-(4-hydroxyphenyl) retinamide (4HPR) as a chemopreventive agent in the presence of agents that potentiates its ability increase the expression of inducible nitric oxide synthase (iNOS, and NO production in cells.

  本文披露了制备N-(4-羟基苯基)视黄酰胺（4HPR）和/或其他视黄醇脂质体组合物的简单且独特的方法。还披露了通过这些方法制备的脂质体4HPR组合物，并将这种组合物用于治疗疾病，如乳腺癌。本发明还提供了一种方法，通过增强诱导型一氧化氮合酶（iNOS）和细胞内NO产生的能力，提高N-(4-羟基苯基)视黄酰胺（4HPR）作为化学预防剂的功效。
• Retinol binding protein and transthyretin modulators for treating diabetes
  申请人：Sirion Therapeutics, Inc.

  公开号：EP1930046A1

  公开（公告）日：2008-06-11

  Described herein are methods and compositions for treating certain retionol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.

  本文描述了通过调节受试者体内转甲状腺素（TTR）和视黄醇结合蛋白（RBP）的可用性来治疗某些视黄醇相关疾病和病症的方法和组合物。例如，这些方法和组合物提供了治疗和/或预防老年性黄斑变性和/或营养不良、代谢紊乱、特发性颅内高压、骨质疏松症以及蛋白质错误折叠和聚集疾病的治疗剂。所公开的组合物可用作单剂疗法，也可与其他制剂或疗法联合使用。此外，本文还描述了用于选择可调节受试者体内 TTR 和 RBP 可用性的适当制剂的方法和检测方法。
• Retinol binding protein and transthyretin modulators for treating hypertosis, Alzheimer's disease or idiopathic intracranial hypertension
  申请人：ReVision Therapeutics, Inc.

  公开号：EP2289500A1

  公开（公告）日：2011-03-02

  Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.

  本文描述了通过调节受试者体内转甲状腺素（TTR）和视黄醇结合蛋白（RBP）的可用性来治疗某些视黄醇相关疾病和病症的方法和组合物。例如，这些方法和组合物提供了治疗和/或预防老年性黄斑变性和/或营养不良、代谢紊乱、特发性颅内高压、骨质疏松症以及蛋白质错误折叠和聚集疾病的治疗剂。所公开的组合物可用作单剂疗法，也可与其他制剂或疗法联合使用。此外，本文还描述了用于选择可调节受试者体内 TTR 和 RBP 可用性的适当制剂的方法和检测方法。
• Use of retinoids to treat high blood pressure and other cardiovascular disease
  申请人：——

  公开号：US20030008919A1

  公开（公告）日：2003-01-09

  This invention provides methods of treating a disease in a mammal where the disease is characterized by a symptom ameliorated by inhibition of cellular calcium influx. The methods involve administering to the mammal an effective amount of a retinoid and a pharmacologically acceptable excipient.

  本发明提供了治疗哺乳动物疾病的方法，该疾病的特征是通过抑制细胞钙离子流入而改善症状。这些方法包括向哺乳动物施用有效量的维甲酸和药理学上可接受的赋形剂。